FDA DEVICE FACTS
BD BBL Sensi-Disc Ceftazidime Avibactam (30/20ug), Antimicrobial Susceptibility Test Disks
Becton, Dickinson and Company
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
Use of BD BBL™ Sensi-Disc™ Ceftazidime avibactam (30/20g) for in vitro agar diffusion susceptibility testing is indicated when there is a need to determine the susceptibility of bacteria to Ceftazidime avibactam. The concentration of 30/20g has been shown to be active in vitro against most strains of microorganisms listed below, as described in the FDA approved drug insert for this antimicrobic. Active In Vitro and in Clinical Infections Against: Complicated Intra-abdominal Infections (cIAI) Gram-negative Microorganisms Escherichia coli Enterobacter cloacae Klebsiella pneumoniae Klebsiella oxytoca Proteus mirabilis Providencia stuartii Pseudomonas aeruginosa Complicated Urinary Tract Infections (cUTI), including Pyelonephritis Gram-negative Microorganisms Citrobacter freundii Citrobacter koseri Escherichia coli Pseudomonas aeruginosa Enterobacter aerogenes Enterobacter cloacae Proteus spp. Klebsiella pneumoniae Active In Vitro Against: Gram-negative Microorganisms Morganella morganii Providencia rettgeri Serratia marcescens
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。